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Available online 11 May 2012Abstract Chronic hepatitis B and C virus (HBV; HBC) infections are worldwide public health challenges. Molecular and genomic
biomarkers for the prediction of long-term risk of end-stage liver diseases in patients affected with chronic viral hepatitis are
important for the clinical management of the diseases. The REVEAL-HBV/HCV study is a community-based prospective cohort study
aimed to evaluate the risk predictors of progression of chronic HBV and HCV in Taiwan. A total of 23,820 participants were enrolled
between 1991 and 1992 from seven townships in Taiwan. Their serum samples were collected at study entry and follow-up exam-
inations and tested for antibodies against HCV (anti-HCV), HBV surface antigen (HBsAg) and e antigen (HBeAg), serum levels of
alanine aminotransferase (ALT), HCV RNA, HBV DNA, HBsAg, and a-fetoprotein. Genotypes and mutant types of HBV and HCV in
serum samples were also examined. Newly developed cases of cirrhosis and hepatocellular carcinoma (HCC) were ascertained
through follow-up examination and data linkage with profiles from the National Cancer Registry, National Health Insurance Data-
base, and Death Certification System. Age, sex, elevated serum levels of ALT, HBV DNA and HBsAg, HBeAg serostatus, HBV geno-
type, family HCC history, and alcohol drinking habits are important biomarkers for the prediction of HBV-related HCC and cirrhosis.
Age, elevated serum levels of ALT and HCV RNA, and HCV genotype are important biomarkers for the prediction of HCV-related
HCC. Risk calculators have been developed for the long-term risk prediction of HCC for patients with chronic HBV and HCV. These
risk calculators have been documented to have good validity for the prediction of risk of HCC and cirrhosis.
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